BOXED WARNING Severe acute exacerbations of hepatitis B after discontinuation (monitor hepatic function); HIV-1 resistance may emerge if used in unrecognized/untreated HIV-1 (subtherapeutic dose) — offer HIV testing.
FDA dosing
Population
Start
Target
Max
Chronic hepatitis B
Adults
100 mg QD
100 mg QD
100 mg QD
Chronic hepatitis B
Pediatric 2-17 yr
3 mg/kg QD (max 100 mg)
3 mg/kg QD (max 100 mg)
100 mg QD
Renal Adjust by CrCl: 30-49 mL/min 100 mg first dose then 50 mg QD; 15-29 100 mg then 25 mg QD; 5-14 35 mg then 15 mg QD; <5 35 mg then 10 mg QD
Hepatic Undefined
Instructions
May be taken with or without food
Do not use with other lamivudine- or emtricitabine-containing products
Oral solution available for pediatric patients requiring <100 mg or unable to swallow tablets
Monitor hepatic function for several months after discontinuation
Cautions
Exacerbations of hepatitis after discontinuation
Risk of HIV-1 resistance if unrecognized/untreated HIV-1
Emergence of resistance-associated HBV substitutions
Lactic acidosis and severe hepatomegaly with steatosis (nucleoside analogues)
Adverse reactions
Ear/nose/throat infections
Sore throat
Diarrhea
Pregnancy APR data show no substantial difference in major birth defects vs background; pregnancy registry available
Lactation Present in human milk; weigh benefits of breastfeeding against maternal need
⚠ BOXED WARNING
Severe acute exacerbation of hepatitis B on discontinuation